PlainRecalls
ModerateActive

CPSC recall · Reported March 18, 2021

Genentech Recalls Prescription Drug Evrysdi Due to Failure to Meet Child Resistant Packaging Requirements; Risk of Drug Exposure through Eye or Skin Absorption (Recall Alert)

The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug expo…

Recall #
21729
Affected scope
About 14,000
Verify with CPSC →
View my saved recalls

Genentech, a member of the Roche Group, of South San Francisco, Calif. recalled This recall involves bottles of the prescription drug Evrysdi, a prescription medicine us… — a moderate-severity action.

Genentech Recalls Prescription Drug Evrysdi Due to Failure to Meet Child Resistant Packag… was recalled by Genentech, a member of the Roche Group, of South San Francisco, Calif. in March 18, 2021. Reason: The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter …. Remedy: Consumers should immediately store Evrysdi in a safe location out of reach and sight of c…. Verify recall #21729 with the CPSC before acting.

The recall

Genentech, a member of the Roche Group, of South San Francisco, Calif. issued this moderate-severity CPSC recall — The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter ….

Moderate
severity level
March 18, 2021
reported

Sourced from official CPSC enforcement records. Verify recall #21729 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This CPSC action (record #21729) was formally reported on March 18, 2021. It is classified under Moderate severity, with a current status of Active. Genentech, a member of the Roche Group, of South San Francisco, Calif. is listed as the recalling firm. Federal records list the affected scope as About 14,000.

The documented reason for this recall is: The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug exposure by contact with skin or eyes. Presc… Distribution information was not included in the agency filing, so consumers should assume broad potential exposure until the firm publishes point-of-sale details. The remedy documented by the agency is: Consumers should immediately store Evrysdi in a safe location out of reach and sight of children. Consumers should inspect the bottle for any leaking. If it is leaking, contact Genentech for a free r… — consumers holding this product should act on that instruction rather than relying on general guidance.

Within the same product category the archive holds 6 closely related recalls — clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category — 14,048 drugs & medications recalls on record

-50005001,0001,5002,000 20052009201220152018202120242026 216

Where this recall sits in the database

Severity2366872097High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 100,165 recalls in the database, 23,668 are high severity, 72,097 moderate, and 4,400 low. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger — we do not rank products by risk from raw recall volume.

Severity

Moderate

Affected scope

About 14,000

Related Recalls

6

0 from same agency

Product description

This recall involves bottles of the prescription drug Evrysdi, a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older. The recalled 100 mL amber bottles have "Evrysdi (risdiplam) for oral solution," the dosage and "NDC 20242-175-07" on the front of the bottle labels.

Reason for recall

The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug exposure by contact with skin or eyes. Prescription drugs must be in child resistant packaging that prevents children from gaining access to the contents as required by the Poison Prevention Packaging Act (PPPA).

Remedy — what to do

Consumers should immediately store Evrysdi in a safe location out of reach and sight of children. Consumers should inspect the bottle for any leaking. If it is leaking, contact Genentech for a free replacement. Consumers can continue to use as directed, as the leakage is not anticipated to impact the safety or efficacy of administered medicine. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water. Genentech is contacting all known purchasers directly.

Recall Profile

Structured summary of the CPSC recall record
Attribute Value
Agency U.S. Consumer Product Safety Commission
Severity class Moderate
Status Active
Recall number 21729
Date reported March 18, 2021
Date initiated March 18, 2021
Recalling firm Genentech, a member of the Roche Group, of South San Francisco, Calif.
Affected scope About 14,000
Distribution Not disclosed
Official source CPSC notice →

Profile values are sourced directly from the official CPSC enforcement record. Source: U.S. Consumer Product Safety Commission.

What to do with this recall

Consumers should immediately store Evrysdi in a safe location out of reach and sight of children. Consumers should inspect the bo…

  • Check the recall number (21729) and product description against the item you own. Search the archive
  • Confirm the current status and remedy on the official CPSC notice before acting. CPSC notice
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official CPSC record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
This recall involves bottles of the prescription drug Evrysdi, a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older. The recalled 100 mL amber bottles have "Evrysdi (risdiplam) for oral solution," the dosage and "NDC 20242-175-07" on the front of the bottle labels.. Recalled by Genentech, a member of the Roche Group, of South San Francisco, Calif.. Units affected: About 14,000.
Why was this product recalled?
The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug exposure by contact with skin or eyes. Prescription drugs must be in child resistant packaging that prevents children from gaining access to the contents as required by the Poison Prevention Packaging Act (PPPA).
What should consumers do?
Consumers should immediately store Evrysdi in a safe location out of reach and sight of children. Consumers should inspect the bottle for any leaking. If it is leaking, contact Genentech for a free replacement. Consumers can continue to use as directed, as the leakage is not anticipated to impact the safety or efficacy of administered medicine. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water. Genentech is contacting all known purchasers directly.
Which agency issued this recall?
This recall was issued by the CPSC on March 18, 2021. Severity: Moderate. Recall number: 21729.
How do I check if my product is affected by a recall?
Check the product description and recall number (21729) against your product. Visit the official CPSC website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
How do I report an injury from a recalled product?
Report injuries to the issuing agency: CPSC at SaferProducts.gov, NHTSA at nhtsa.gov/report-a-safety-problem, or FDA via MedWatch. Document the product (photos, model/serial numbers, purchase receipts) and seek medical attention. Injury reports help agencies track hazard patterns and may strengthen enforcement actions.

Nearby Recalls in This Category

Other recalls in the same product category — useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with Nicotine Transdermal System Patch, 14 mg, 14 patches per bo… →

Data Sources

Source: FDA, CPSC, and NHTSA federal recall databases. This recall: CPSC, reported March 18, 2021.

  • Source: FDA — Food and Drug Administration, openFDA Enforcement API (food, drug, and medical device recalls)
  • Source: CPSC — Consumer Product Safety Commission Recalls API (consumer product recalls and hazards)
  • Source: NHTSA — National Highway Traffic Safety Administration Recalls API (vehicle safety recalls)

Recall information is sourced from official federal agency databases. Always verify recall details with the issuing agency for the most current status. This information is for research and awareness purposes only.

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records — no number is typed in by an editor. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of June 2026.